Biotech startup Structure pulls off rare IPO, raising $161M
Bio Pharma Dive
FEBRUARY 2, 2023
The company’s lead drug could be an oral alternative to marketed diabetes and obesity drugs from Novo Nordisk and Eli Lilly
Thu.Feb 02, 2023
360 
US FDA approves GSK’s Jesduvroq to treat anaemia of CKD
Pharmaceutical Technology
FEBRUARY 2, 2023
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline ’s (GSK) Jesduvroq (daprodustat) to treat anaemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least four months.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Karuna, hoping to find new brain drugs, buys up a shuttering biotech’s pipeline
Bio Pharma Dive
FEBRUARY 2, 2023
Though Goldfinch Bio focused on kidney diseases, Karuna believes its experimental drugs may have potential treating psychiatric and neurological conditions
Magazine: CRISPR gene therapies cut through in 2023
Pharmaceutical Technology
FEBRUARY 2, 2023
If things go as per plan, in a few months, the US Food and Drug Administration (FDA) will deliberate on the first-of-its-kind CRISPR-based gene therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.
GSK moves hepatitis B drug into late-stage testing
Bio Pharma Dive
FEBRUARY 2, 2023
The British drugmaker sees potential for the medicine to be a functional cure for chronic infections, and is beginning two Phase 3 trials to test its promise
Cidara Therapeutics expands partnership with WuXi XDC
Pharmaceutical Technology
FEBRUARY 2, 2023
Cidara Therapeutics has announced the expansion of its existing collaboration with WuXi XDC for advancing the CD73 oncology DFC programme.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
MD Anderson partners with Federation Bio to develop microbiome therapy
Pharmaceutical Technology
FEBRUARY 2, 2023
The University of Texas MD Anderson Cancer Center has announced a strategic collaboration with Federation Bio for the development of a new microbiome treatment for immunotherapy-resistant cancer patients.
Lilly reports fast sales for new diabetes drug
Bio Pharma Dive
FEBRUARY 2, 2023
Still, fourth quarter sales for Mounjaro were slightly below high Wall Street forecasts and didn’t offset falling revenue from Lilly’s COVID-19 antibodies
Endevica Bio and Orbit Discovery unite to boost cachexia therapeutics
Pharma Times
FEBRUARY 2, 2023
The central focus of the agreement is to establish peptide hits from selected library populations
Roche promotes from within to replace departing pharma head
Bio Pharma Dive
FEBRUARY 2, 2023
Teresa Graham, currently head of Roche Pharmaceuticals’ global product strategy, will succeed former chief Bill Anderson. The reshuffle is one of several recent changes in the pharma’s leadership
2022 Research: The Rapid Rise of Ocean Freight Visibility
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
Bill & Melinda Gates Foundation funding for MIP Discovery
Pharma Times
FEBRUARY 2, 2023
Boost concerns rapid deployment of novel detection reagents for testing in low to middle-income countries
Amid mainstream hype, Eli Lilly takes a hard line marketing its buzzy diabetes med Mounjaro
Fierce Pharma
FEBRUARY 2, 2023
Amid mainstream hype, Eli Lilly takes a hard line marketing its buzzy diabetes med Mounjaro fkansteiner Thu, 02/02/2023 - 11:20
Pfizer sees all-time high for 2022 revenues; but declining COVID-19 products market will hit 2023 sales
BioPharma Reporter
FEBRUARY 2, 2023
Pfizer expects to see a 64% drop in Comirnaty revenues this year, which will hit its 2023 revenue guidance. Markets & Regulations
Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act
FDA Law Blog
FEBRUARY 2, 2023
By Mark A. Tobolowsky & Charles G.
An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
BioNTech completes first in-house plasmid DNA manufacturing facility
BioPharma Reporter
FEBRUARY 2, 2023
mRNA pioneer BioNTech has completed construction of its first proprietary plasmid DNA manufacturing facility in Marburg, Germany. Upstream Processing
Fierce Pharma Asia—J&J, Legend's CAR-T win; Sanofi's India job cuts; BeiGene, Novartis' PD-1 delay
Fierce Pharma
FEBRUARY 2, 2023
Fierce Pharma Asia—J&J, Legend's CAR-T win; Sanofi's India job cuts; BeiGene, Novartis' PD-1 delay aliu Thu, 02/02/2023 - 15:58
Vector BioMed Makes Company Debut
Pharmaceutical Commerce
FEBRUARY 2, 2023
CDMO will be providing high-quality lentiviral vectors for CAR-T therapies.
Novo's Rybelsus comes into its own as Wegovy shakes off supply constraints
Fierce Pharma
FEBRUARY 2, 2023
Novo's Rybelsus comes into its own as Wegovy shakes off supply constraints fkansteiner Thu, 02/02/2023 - 08:57
Mandatory COVID Vaccination Policy Template
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
George Church-Backed Thymmune Launches to Target Overlooked Organ
BioSpace
FEBRUARY 2, 2023
George Church-Backed Thymmune Launches to Target Overlooked Organ 3/2/2023
Roche taps insider Graham for top pharma job as setbacks prompt M&A questions
Fierce Pharma
FEBRUARY 2, 2023
Roche taps insider Graham for top pharma job as setbacks prompt M&A questions aliu Thu, 02/02/2023 - 10:46
Lilly Bets $630M on Pain Target Novartis Failed
BioSpace
FEBRUARY 2, 2023
Lilly Bets $630M on Pain Target Novartis Failed 3/2/2023
Bristol Myers holds on to blockbuster Sotyktu hopes, plays down Otelza threat
Fierce Pharma
FEBRUARY 2, 2023
Bristol Myers holds on to blockbuster Sotyktu hopes, plays down Otelza threat zbecker Thu, 02/02/2023 - 13:22
Is a 4-Day Workweek Possible for Biopharma?
BioSpace
FEBRUARY 2, 2023
Is a 4-Day Workweek Possible for Biopharma? 3/2/2023
How AbCellera helps partners propel their antibody therapies to the clinic
Fierce Pharma
FEBRUARY 2, 2023
How AbCellera helps partners propel their antibody therapies to the clinic jpiatt Thu, 02/02/2023 - 10:34
MorphoSys Cuts Pre-Clinical Programs, 17% of Staff
BioSpace
FEBRUARY 2, 2023
MorphoSys Cuts Pre-Clinical Programs, 17% of Staff 3/2/2023
New patent expiration for Pf Prism drug CHANTIX
Drug Patent Watch
FEBRUARY 2, 2023
Annual Drug Patent Expirations for CHANTIX Chantix is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from three suppliers. There are two… The post New patent expiration for Pf Prism drug CHANTIX appeared first on DrugPatentWatch - Make Better Decisions. Patent Expiration
Amgen’s Amjevita Enters Market as First Humira Biosimilar, But at Two Different Price Points
XTalks
FEBRUARY 2, 2023
Amgen’s Amjevita, the first biosimilar version of AbbVie’s blockbuster arthritis injection Humira (adalimumab), has finally hit the market this week after fetching US Food and Drug Administration (FDA) approval back in 2016.
New patent for Galderma Labs drug EPSOLAY
Drug Patent Watch
FEBRUARY 2, 2023
Annual Drug Patent Expirations for EPSOLAY Epsolay is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from one supplier. There are five… The post New patent for Galderma Labs drug EPSOLAY appeared first on DrugPatentWatch - Make Better Decisions. Patent Added
Abbott Labs Under Investigation by the DOJ + Robot Dishwashers for the Foodservice Industry – Xtalks Life Food Podcast Ep. 95
XTalks
FEBRUARY 2, 2023
Multinational medical device and health care company Abbott Laboratories is under investigation by the US Department of Justice (DOJ) following the closure of Michigan’s baby formula plant in February 2022.
Merck's recent Keytruda label expansion in NSCLC is more of a 'long-term' opportunity, CEO says
Fierce Pharma
FEBRUARY 2, 2023
Merck's recent Keytruda label expansion in NSCLC is more of a 'long-term' opportunity, CEO says kdunleavy Thu, 02/02/2023 - 10:43
Say hello to our new look!
BioPharma Reporter
FEBRUARY 2, 2023
BioPharma-Reporter is revealing a brand-new design, including a new log and website with improved usability. Headlines
Say hello to our new look!
Outsourcing Pharma
FEBRUARY 2, 2023
Here at OutsourcingPharma, we put our audience at the heart of what we do. For many years, we have provided our readers with a 360-degree view of the pharma landscape and our editorial standards remain unsurpassed. Headlines
Let's personalize your content